Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

The neurobiology and treatment of first-episode schizophrenia

R S Kahn, I E Sommer

Molecular Psychiatry · 2014 · Review

doi:10.1038/mp.2014.66

Abstract

It is evident that once psychosis is present in patients with schizophrenia, the underlying biological process of the illness has already been ongoing for many years. At the time of diagnosis, patients with schizophrenia show decreased mean intracranial volume (ICV) as compared with healthy subjects. Since ICV is driven by brain growth, which reaches its maximum size at approximately 13 years of age, this finding suggests that brain development in patients with schizophrenia is stunted before that age. The smaller brain volume is expressed as decrements in both grey and white matter. After diagnosis, it is mainly the grey matter loss that progresses over time whereas white matter deficits are stable or may even improve over the course of the illness. To understand the possible causes of the brain changes in the first phase of schizophrenia, evidence from treatment studies, postmortem and neuroimaging investigations together with animal experiments needs to be incorporated. These data suggest that the pathophysiology of schizophrenia is multifactorial. Increased striatal dopamine synthesis is already evident before the time of diagnosis, starting during the at-risk mental state, and increases during the onset of frank psychosis. Cognitive impairment and negative symptoms may, in turn, result from other abnormalities, such as NMDA receptor hypofunction and low-grade inflammation of the brain. The latter two dysfunctions probably antedate increased dopamine synthesis by many years, reflecting the much earlier presence of cognitive and social dysfunction. Although correction of the hyperdopaminergic state with antipsychotic agents is generally effective in patients with a first-episode psychosis, the effects of treatments to correct NMDA receptor hypofunction or low-grade inflammation are (so far) rather modest at best. Improved efficacy of these interventions can be expected when they are applied at the onset of cognitive and social dysfunction, rather than at the onset of psychosis.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

When does schizophrenia first manifest itself? Is it at the onset of the first psychosis? Is it at the first signs of psychosis, as in the group of patients referred to as ‘at-risk mental state' (ARMS)? Or is it even earlier, and not primarily associated with psychosis, but with cognitive decline? This question is not only essential to address the biology of first-episode schizophrenia, but it is at the core of the schizophrenia concept itself.

We have argued that the first signs of schizophrenia already occur in early puberty with a (relative) decline in cognitive dysfunction. It is not until many years later, when psychotic symptoms occur during the ARMS, or more pronounced during the first psychosis itself, that the diagnosis becomes obvious. Thus, we would argue that first-episode schizophrenia is a misnomer, as the core of the illness, that is, the cognitive decline, may not be episodic. Nevertheless, almost all studies into the biology of the first stages of schizophrenia have focused on the psychotic symptoms to define the onset of the illness.

Brain changes at the time of first psychosis

It is evident that once psychosis is present in patients with schizophrenia, the underlying biological process of the illness has already been ongoing for many years. This conclusion can be based on the multitude of neuroimaging studies that we recently reviewed in a meta-analysis of over 18 000 subjects, including 771 medication-naive, recent onset patients. These data show a slight, but significant, decrease in intracranial volume in patients with schizophrenia (effect size−0.2), in chronic and recent onset, medication-naive patients. Intracranial volume is driven by brain growth, as it is the enlarging brain that determines the expansion of the skull., The growing brain reaches its maximum size at approximately 13 years of age. Therefore, brain development must be stunted in patients with schizophrenia before that time. From the same meta-analysis, it can be gleaned that there must be additional brain loss, or continued abnormal development, after the age of 13: total brain volume in never-treated patients is decreased to a larger degree (effect size−0.4) than is intracranial volume and this is due to decreases in both white and grey matter. Importantly, while grey matter loss is larger in chronic than in medication-naive patients, white matter volume is decreased to a similar extent in both groups. Indeed, longitudinal studies indicate that loss of white matter volume, while present at psychosis onset, does not progress further after psychosis has emerged. This is consistent with the finding in twin studies that decreased white matter volume in schizophrenia may be related more to the genetic risk to develop the illness than to the effects of illness itself. In contrast, grey matter volume loss (mainly expressed as reductions in cortical thickness) progresses further after the onset of psychosis, and is related to outcome, cannabis smoking, medication use, and psychotic relapses. Thus, although some of the brain abnormalities in schizophrenia worsen after the onset of psychosis, abnormal development of the brain must have been ongoing for many years before the first psychosis—expressed, as it is, in decreased intracranial volume and even larger decreases in white and grey matter.

What is the nature of the white and grey matter changes that are present at the onset of the first psychosis? Using tract-based analysis of white matter fibres in medication-naive schizophrenia patients we, and others, have found differences in the uncinate and arcuate fasciculi, suggestive of axonal or glial damage and/or increased free water concentrations., In unmedicated first-episode psychosis (FEP) patients reduced fractional anisotropy, a measure reflecting white matter fibre density and myelination, is related to cognitive dysfunction. Pronounced fractional anisotropy reductions in medication-naive FEP patients appear to be predictive of poor response to subsequent antipsychotic treatment. While white matter decreases are not evenly dispersed throughout the brain, but instead are most pronounced in association fibres, such as the uncinate and arcuate fasciculi, changes in the grey matter are not uniformly distributed throughout the brain either. Most pronounced grey matter decreases in FEP patients are found in frontal and temporal areas, including the insula, superior temporal gyrus and the anterior cingulate gyrus., As indicated, following the FEP, most (but not all) longitudinal studies suggest that grey matter loss continues, which is most prominent in frontal and temporal areas, and results from cortical thinning (and not surface shrinkage) and is related to clinical and cognitive outcome.,,,, Only few studies have investigated white matter changes over time after the FEP. Two recent studies showed contrasting results with one demonstrating improvement of white matter deficits in FEP patients after antipsychotic treatment and the other showing worsening of these abnormalities. On postmortem examination, decreases in white matter are associated with a reduction in oligodendrocytes in the superior frontal cortex and in the bilateral hippocampus, suggesting dysfunction of oligodendrocytes to underlie white matter deficits in schizophrenia.

Brain changes before the onset of the first psychosis

The ARMS is a prodromal phase of schizophrenia characterized by cognitive impairments, mood alterations, anxiety, attenuated psychotic symptoms and a decline in social and occupational functioning. Although the concept has been useful in understanding the development of schizophrenia, only a small percentage of patients with these symptoms eventually go on to develop the illness—and this percentage further declines as the number of studies increases.

A recent review on neurobiological changes in ARMS subjects suggests that volumes of frontal and temporal areas are decreased in a similar fashion—but to a lesser extent—as observed in schizophrenia. Longitudinal studies are scarce, but those available suggest that grey matter deficits present in those subjects that go on to develop schizophrenia, worsen over time and are found mainly in fronto-temporal areas., Progressive reduction in the integrity of frontal white matter has also been reported in ARMS subjects who go on to develop schizophrenia. However, studies in the ARMS period are limited by the fact that the subjects studied are selected on the basis of the presence of mild and incomplete symptoms of psychosis and that outcome, that is, conversion, is defined by psychosis as well. It has been argued that a focus on cognitive and negative symptoms in these ARMS subjects may be needed to understand the developmental biology of schizophrenia. Indeed, baseline cognitive functioning in ARMS subjects is an adequate predictor of poor outcome, regardless of transition to psychosis.,,

Possible causes and effects of the brain changes

To understand the possible causes of the brain changes in the first phase of schizophrenia, evidence from treatment studies, postmortem and neuroimaging investigations together with animal experiments needs to be integrated. These studies suggest that schizophrenia is related to at least three interacting pathophysiological mechanisms: dopaminergic dysregulation, disturbed glutamatergic neurotransmission and increased proinflammatory status of the brain. These processes interact with each other and most likely have causal interrelationships.

Dopamine dysregulation

Since the discovery of the antipsychotic properties of chlorpromazine in the 1950s, increased dopamine (DA) turnover in the striatum has received much attention as an underlying mechanism of schizophrenia. Although initial studies focused on the postsynaptic DA receptor, more recent positron emission tomogrpahy (PET) studies, using (18)F-DOPA as a tracer, show that the major locus of dopaminergic dysfunction is presynaptic rather than postsynaptic in nature, characterized by elevated DA synthesis and release capacity. Increased (18)F-DOPA binding capacity is already present during the ARMS period and is found to be predictive of the further development into full clinical psychosis,, (see Table 1A for an overview of DA deviations in ARMS subjects). In medication-naive schizophrenia patients who experience an FEP, increased striatal DA synthesis is a rather consistent finding (an overview is provided in Table 1B). Although increased striatal DA synthesis may be the final common pathway to psychotic symptoms,, its relation to cognitive symptoms is less clear. In a mouse model, increased postsynaptic striatal DA receptors could evoke cognitive dysfunction in several domains, but this has not been tested directly in humans.

N-methyl-D-aspartate receptor hypofunction

In fact, some of the cognitive dysfunction in schizophrenia may be related to a different neurotransmitter complex, the N-methyl-D-aspartate receptor (NMDAr)/glutamate system. It has been hypothesized that the NMDAr, situated between the primary and secondary glutamatergic cortical neurons, constitutes the main deficit underlying schizophrenia. Poor function of the NMDAr, in turn, renders the gamma-amino-buteric-acid (GABA)-ergic interneuron less effective. This loss of GABA-ergic firing provides insufficient inhibition of the secondary glutamatergic neurons, allowing them to fire more often but with less synchrony, directly causing the excessive firing of DA neurons in the mesolimbic pathway. This hypothesis is based on studies using NMDAr antagonists, such as ketamine and phencyclidine, which were found to induce the full range of schizophrenia symptoms, including psychosis, negative symptoms, and also cognitive dysfunction. Furthermore, patients with an autoimmune encephalitis producing antibodies against the NMDAr can have a clinical picture that is indistinguishable from schizophrenia. Finally, many of the well-known risk genes, such as DISC-1, dysbindin, SHANK and NRG-1,, but also de novo mutations associated with schizophrenia influence glutamatergic neurotransmission.

During brain development the NMDAr has a crucial role in brain maturation by means of synaptic plasticity, which forms the basis for adequate development of higher cognitive functions, such as learning and memory (see Wang et al.). NMDAr is a hetero-tetrameric structure with one obligate NR1 and two variable NR2 subunits, determining its biophysical and pharmacological properties. During brain development, the subunit composition of this receptor undergoes a switch, in which some subunits are replaced by structurally different ones. The mature receptor composition has different physiological properties, rendering the receptor more suitable for optimal timing of firing, thereby enabling the swift integration of environmental stimuli. The timing of receptor switches differs per brain region, and may coincide with ‘risk windows' for schizophrenia, that is, developmental phases when the individual is particularly vulnerable to environmental influences such as hypoxia, birth stress, infection or inflammation, drug abuse or social isolation.,, During pregnancy, fetal NMDAr levels are increased, rendering the infants' brain vulnerable to insults. It is conceivable, although largely hypothetical, that environmental risk factors for schizophrenia affect the brain by means of delaying or preventing adequate NMDAr switching in specific brain areas, and an incomplete receptor switch could be related to the onset of cognitive decline in the earliest phases of the illness. Imperfect expression of the mature NMDAr subunit profile is likely to impair the process of long-term depression and potentiation, by which frequently-used connections are strengthened and rarely-used connections are weakened. At early adolescence, pruning will eliminate the weak connections. When a lack of long-term depression and potentiation has resulted in a failure to differentiate the frequently-used from the rarely-used connections, pruning may become a random process, eliminating important as well as less-relevant connections.

Downstream from the glutamatergic neurons, decreased functioning of the NMDAr leads to hypofunction of the inhibitory GABA-ergic interneurons. Decreased functioning of these fast-spiking GABA-ergic interneurons hampers synchronisation of neuronal firing of the pyramidal neurons. Diminished synchronized neuronal activity leads—again—to impaired cognitive processing. Postmortem studies consistently demonstrate that a subpopulation of the GABA-ergic interneurons, the parvalbumin-containing chandelier cells, is decreased in patients with schizophrenia (for a review see Curley et al.). Enzymes related to GABA-ergic neurotransmission, such as glutamic acid decarboxylase (GAD)67 and GABA transporter (GAT)1, are consistently reported to be decreased in patients with schizophrenia. A large postmortem study involving 240 controls of all age categories and 31 patients with schizophrenia observed that development and maturation in the prefrontal cortex and the hippocampus is characterized by progressive switches in expression from GAD25 to GAD67 and from NKCC1 to KCC2. The former switch leads to GABA synthesis, and the latter leads to switching from excitatory to inhibitory neurotransmission. In the hippocampus, GAD25/GAD67 and NKCC1/KCC2 ratios are increased in patients with schizophrenia, reflecting a potentially immature GABA physiology. This deviation was associated with the risk allele at the promoter region of the GAD-1 gene.

It remains unclear whether deviations in the GABA-ergic interneurons are secondary to deficits in NMDAr-mediated signalling, or if abnormal NMDAr signalling is compensatory to GABA-ergic aberrations. Either way, hypofunction of the NMDAr and reduced neural synchrony caused by decreased function of the GABA-ergic interneurons may be the converging mechanisms underlying cognitive dysfunction, which—as indicated—starts at least 10 years before the onset of psychotic symptoms and remains relatively stable after the FEP, as a 10-year follow-up study of FEP patients showed no clear signs of deterioration as compared with healthy controls. Murine studies show that glutamatergic afferents from the hippocampus to the nucleus accumbens exert a strong excitatory effect on striatal DA neurons, influencing both activity and firing properties of the dopaminergic neurons. Thus, decreased activation of the NMDAr leads to an increase in striatal DA release and induce psychotic symptoms. This finding provides a biological explanation of the clinical and epidemiological observations that cognitive changes precede the onset of psychosis by many years.

One of the few available techniques to examine the status of the NMDA/glutamate system in the human brain is the use of magnetic resonance spectroscopy (MRS). This method provides concentrations of several molecules, including glutamate, glutamine and GABA. However, glutamate as measured with MRS does not reflect intrasynaptic glutamate levels, as the MRS signal is derived from glutamate in neurons, blood vessels, white matter, and so on. When glutamate is released into the synapse it is quickly metabolized into the inert glutamine, which may be a better reflection of intrasynaptic glutamate levels and hence of NMDAr hypofunction. Indeed, Rowland et al. found increased glutamine as measured with MRS after infusion of ketamine in healthy subjects. Moreover, with magnetic resonance imaging scanners at a magnetic field strength lower than 4 Tesla, it is difficult to disentangle the peaks from glutamate and glutamine; most studies therefore provide a value of ‘glx', which is composed of both glutamate and glutamine. Results in schizophrenia suggest that glx concentrations are different for each stage of the illness.

Although results in ARMS subjects are not consistent, the majority of studies show increased glx,,,,, whereas a few report decreased, or normal, values (see Table 2A). Studies differentiating between glutamate and glutamine generally report increased levels of both molecules. In medication-naive FEP patients, studies generally report increased glx concentrations (composed of increased glutamate and increased glutamine) as compared with healthy controls,,,, whereas in medicated FEP patients, glx levels are reported to be normal (Table 2B).,,, In the later phases of schizophrenia, glx values appear slightly but significantly decreased, which is the result of decreased glutamate and increased glutamine levels, leading to an increased glutamine-to-glutamate ratio., The decreased glx levels in chronically medicated patients are most pronounced in the frontal areas and correlate with cognitive deficits.

GABA levels have been measured less extensively but the few available reports generally indicate decreased GABA levels in medicated FEP as well as in chronic patients, and these are correlated with cognitive dysfunction,,, but see Tayoshi et al. Detailed information on GABA levels in ARMS subjects and in unmedicated FEP patients is as yet unavailable.

Increased proinflammatory status

The third mechanism that may underlie (some of the) the signs and symptoms of schizophrenia is an increased proinflammatory status of the brain, a hypothesis proposed many years ago, for example, by Stevens who observed signs of low-grade inflammation in postmortem brains of patients with schizophrenia. Interest in inflammation as a possible aetiology of schizophrenia has been bolstered by the simultaneous publication of three genome-wide association studies in 2009 providing compelling evidence for the involvement of the MHC region in the susceptibility of schizophrenia.,, MHC class I molecules could also operate through direct effects on brain development as these molecules regulate many aspects of brain development, including neurite outgrowth, synapse formation and function, homeostatic plasticity and activity-dependent synaptic refinement.,, However, epidemiological studies consistently show that the risk for schizophrenia is increased following pre and perinatal infections. Moreover, a nation-wide registry study has shown that both (familial) autoimmune disorders and a history of infection (severe enough to need hospital admittance) increase the risk to develop schizophrenia. A subset of patients initially diagnosed with schizophrenia is known to suffer from autoimmune encephalitis. A recent study demonstrated anti-NMDAr antibodies in almost 10% patients with schizophrenia as compared with 0.4% in controls, but replication of this finding is needed.

However, neuroinflammation probably has a role in a larger group of patients, not just in those who can be characterized as suffering from an autoimmune encephalitis.

The immature brain can be exposed to inflammation associated with viral or bacterial infection or as a result of sterile brain insults. Microglia are the main immuno-competent cells in the immature brain, and depending on the stimulus, molecular context and timing, these cells will acquire various phenotypes, which are critical regarding the consequences of inflammation. Acute inflammation can shift to a chronic inflammatory state and adversely affect brain development.

Support for the putatively increased activation of microglia cells is provided by two studies using 11C-PK11195 PET, reporting increased activation of microglia cells especially in the temporal lobes in patients with early-stage schizophrenia as compared with controls., A third PET study using another tracer (11C-DAA1106) found no differences between schizophrenia patients and controls. Specificity of both tracers for microglia activation is under discussion, however. A possible explanation for the difference is that the latter PET study included chronic patients and increased neuroinflammation may be present only in the first years of the disease. If this would be the case, then postmortem studies—usually including only chronic patients—would not be expected to find signs of increased inflammation. However, although results are inconsistent, many postmortem studies, in fact, do report increased numbers of microglia cells in activated states. Table 3 provides a summary of these findings. Only one postmortem study analysed brain tissue of patients with long and short duration of illness and, surprisingly, reported strongest indications of increased inflammation in the later stages of the illness. Postmortem literature, which mainly describes the late stages of schizophrenia, may therefore not be representative for the presence (or absence) of increased proinflammatory status of the brain in patients with an FEP. Information on a potential proinflammatory status in FEP patients can be retrieved from peripheral blood markers, which so far show that deviations in pro and antiinflammatory factors are of the same magnitude in FEP patients as in chronic patients with acute exacerbations.

When microglial cells become activated, they abandon their neurotrophic functions (for example, axon guidance and the production of neurotrophins such as BDNF), which leave the neurons in suboptimal condition. In addition, activated microglia produce several neurotoxic substances, such as free radicals and proinflammatory cytokines that can damage neuronal and glial cells, leading to cognitive dysfunction and brain volume loss. Neuroinflammation and NMDAr dysfunction are interwoven in several ways. For example, activated microglial cells produce high levels of glutamate, whereas NMDAr activity is required for the expression of antioxidant enzymes, necessary to compensate the toxic effects of microglial activation. Furthermore, deviant brain development and subsequent cognitive alterations in adulthood may be mediated by cytokines, especially by IL-6 induction during infection. Activation of the IL-6/Nox2 pathway and consequent increase in superoxide production in the brain can also induce a loss of parvalbumin-containing interneurons in adulthood. The increased glutamate levels observed with MRS in the ARMS and early FEP period may thus result from activated microglial cells rather than from NMDAr hypofunction. The increased proinflammatory status can also cause or worsen hypoactivation of the NMDAr by means of altered tryptophane catabolism. During low-grade inflammation, the catabolism of tryptophane in the brain is shifted away from serotonin as an end product towards kynurenic acid, which inhibits the NMDAr at the glycine site. One postmortem study and several studies investigating cerebrospinal fluid indeed showed increased levels of kynurenic acid in patients with schizophrenia as compared with controls (reviewed by Coyle). Inflammation can also be linked to DA dysregulation, as animal studies consistently show increased activity of mesolimbic DA neurons in offspring of rodents exposed to prenatal inflammatory challenges. In fact, the white matter alterations observed in the early stages of schizophrenia, before psychotic symptoms have become apparent, could reflect an increased inflammatory status of the brain.

Not all schizophrenia patients have the same pathophysiology

It is highly unlikely that the pathogenesis of all patients with schizophrenia will be uniform. More probable is that some patients will display for example pronounced NMDAr hypofunction, whereas in others this mechanism is hardly affected. Indeed, Egerton et al. have found that FEP patients who respond well to antipsychotic medication displayed normal glx levels in the anterior cingulate cortex, whereas those with poor response showed increased glx concentrations, indicating that in the nonresponders, other mechanisms than increased DA synthesis may have a role. Demjaha et al. confirmed that patients with intractable psychosis, not responding to various antipsychotic agents, lacked the typical increase in DA synthesis capacity. In a similar vein, increased proinflammatory status of the brain may be most pronounced in a specific subgroup of patients. Indeed, in 180 medication-naive FEP patients, approximately one-third showed marked increases in serum immunity markers. In parallel, a recent postmortem study indicated signs of low-grade inflammation in 40% patients with schizophrenia. For future research, it will be key to determine deviations in DA synthesis, NMDAr hypofunction and proinflammatory status of the brain on the subject level so that these mechanisms can be targeted on an individual basis. Neuroimaging techniques to visualize striatal DA synthesis, frontal glutamine levels and activation of microglial cells could unravel which underlying neurobiology is relevant in a specific patient.

Treatment of first-episode schizophrenia

For obvious reasons, treatment of schizophrenia has focused almost exclusively on the stage when patients present with clear-cut clinical symptoms, that is, psychosis. Although an increasing number of studies are now developing treatment at the earlier stages of the illness, such as the ARMS, or focus on the alleviation of cognitive dysfunction in chronic patients, the bulk of studies still focus on the treatment of psychosis.

Antipsychotic treatment

The best-known mechanism of action of antipsychotic medication is the correction of increased striatal DA turnover. Interestingly, more recent work in animals (Kato et al.), and cultured brain cells (Zheng et al.) suggest that inhibition of microglial activation may be an additional aspect of the efficacy of antipsychotics. Although we have had effective antipsychotic treatments for nearly 50 years, the application and implementation of these treatments is far from optimal. Many of the elementary questions in the treatment of schizophrenia have remained unanswered. Fortunately, first-episode patients do often respond reasonably well; the main challenge then becomes how to keep them well. Once it has been decided that antipsychotic treatment is to be initiated, the question arises on how to prioritize the currently available treatments in a rational and optimal manner. No one treatment will be adequate for all patients. Prospective, sequential studies are necessary to develop treatment algorithms for schizophrenia, but these are almost completely missing. Although every year hundreds of studies on schizophrenia are published (the register of the Cochrane Schizophrenia Group currently includes 12 000 controlled clinical trials), most of the studies focus on the question of whether a specific drug or psychotherapeutic intervention works or not. However, lacking are the mechanism-based, rational, sequential studies that address how to deal with treatment nonresponse. Although schizophrenia patients with an FEP are highly responsive to antipsychotic medication, this rapidly diminishes as episodes increase. Whether switching of antipsychotics is helpful in such patients has hardly been studied, although several large trials are currently under way (OPTiMiSE trial and SWITCH). Agid et al. used an algorithm in which 244 FEP patients were randomized to risperidone or olanzapine. After 4 weeks, as much as 75% had responded to medication (82% in the olanzapine group and 66% in the risperidone group). Nonresponders were switched to the other arm. In this second trial, response rate dropped dramatically to only 17% and again significantly more patients in the olanzapine than in the risperidone group responded. This study illustrates the high response rate in FEP patients, but also shows that patients who do not respond to the first antipsychotic medication have a low probability of responding to a second antipsychotic drug. In these nonresponders, non-dopaminergic mechanisms may be important and when a first trial of antipsychotic medication has failed, treatments to correct NMDAr hypofunction, or increased proinflammatory status of the brain, are expected to be more effective.,,

Glutamatergic treatments

There are several routes that can potentially improve, or compensate, NMDAr hypofunction in schizophrenia. First, the availability of glycine or D-serine at the glycine site can be increased by the administration of glycine or D-serine. Some studies suggest that glycine and D-serine modestly improve positive and negative symptoms, with little or no impact on cognitive dysfunction. D-serine levels can also be increased by inhibiting its cataboliser D-amino acid oxidase (DAAO), which so far showed no efficacy on symptom severity.

Modulations of AMPA receptors, which are colocalized in synapses near NMDA receptors, provide another avenue for treatment. Several compounds such as CX-516, piracetam cyclothiazide and LY404187 have been tested but so far have not shown clear benefits. A third option is modulation of the glycine transporter, for example, with sarcosine, which has demonstrated some improvement in negative and cognitive symptoms. Finally, modulation of the metabotropic glutamate receptor (mGluR) has been studied: in a phase II study, one of these substances (LY354740), was comparable in efficacy to olanzapine, but a subsequent larger trial was inconclusive.

Influencing GABA-ergic interneurons—the downstream relays of the glutamatergic neurons—offers an alternative strategy. Two classes of selective GABA-ergic drugs have been proposed to enhance cognition in schizophrenia, α5-selective inverse agonists and α2/3-selective agonists. There is compelling evidence from animal models of schizophrenia that allosteric modulation of the α5 subunit of the GABA-A receptor can correct underlying deviations and lead to improvements in cognition. So far, significant improvement of cognition in patients with schizophrenia by GABA-ergic drugs has not been demonstrated, however. The disappointing results with agents targeting NMDAr-mediated or GABA-ergic signalling may not come as a surprise given the fact that dysfunction within these circuits is likely to take place far earlier than does the onset of psychosis. At the time of frank psychotic symptoms many years of NMDAr and GABA-ergic hypofunction may already have caused irreversible deficits in brain maturation and synaptic plasticity. Therefore, treatment for schizophrenia may only be truly effective during the critical developmental window, after which the brain is hard -wired. For treatment, or better prevention, of cognitive decline, it will be key to diagnose at-risk subjects much earlier than the FEP or even the ARMS stage so that glutamatergic or GABA-ergic medication can be given before the window of opportunity has closed.

Antiinflammatory agents for the treatment of schizophrenia

The use of antiinflammatory agents to improve symptoms of schizophrenia is still in its infancy. A recent meta-analysis has shown some efficacy in schizophrenia for aspirin, n-acetylcysteine (NAC) and estrogens (the latter only in females), but not for other agents with antiinflammatory properties, such as celecoxib, minocycline, davunetide and polyunsaturated fatty acids. Two EEG studies showed that NAC improved both multivariate phase synchronization and mismatch negativity in patients with schizophrenia., A trial in ARMS subjects, however, did show that polyunsaturated fatty acids significantly reduced (or delayed) transition to psychosis. A follow-up study of this RCT showed that a reduction of positive symptoms and a lower mean PANSS positive score in the polyunsaturated fatty acids group were apparent after 8 weeks, whereas the significant drop in negative symptoms and the higher mean scores in global functioning occur later at 12 weeks. More studies are needed, however, before this treatment can be considered an effective intervention.

As increased proinflammatory status may also affect the brain in an early stage of the illness, augmentation with these agents during the ARMS or FEP stages may be less effective than earlier interventions, that is, several years before psychosis starts. As the diagnosis of schizophrenia is currently based on the onset of the psychotic symptoms, irreversible damage to neurons and glia cells, reflected in brain volume loss, may already be present at the time of diagnosis (as has been argued above and has been repeatedly shown in magnetic resonance imaging studies). Thus, to treat the earliest phases of the illness, antiinflammatory agents with high numbers-needed-to-harm are the best candidates. NAC may be of particular interest, as this component targets not only a diverse array of factors including glutamatergic neurotransmission, the antioxidant glutathione, neurotrophins, apoptosis, mitochondrial function, but also the inflammatory pathways. NAC displays a benign side-effect profile and may even have some anti-addictive properties, which would make this component a valuable substance for prevention of brain volume loss, cognitive deterioration and subsequent transition to psychosis in individuals at (genetic) risk for schizophrenia.

Non-pharmacological treatments

Among the many non-pharmacological interventions recently developed to treat patients in the ARMS and FEP period, exercise interventions, such as aerobic interval training, seem especially appealing. The beneficial effects of exercise on mood and self-esteem have long been acknowledged and we recently showed that psychotic and negative symptoms are also reduced by exercise interventions as compared with creative therapy. Interestingly, physical exercise is known to affect gene expression in an antiinflammatory pathway, including the downregulation of monocyte TNF, TLR4 and CD36 genes. In sedentary patients, a fitness programme engaging them in a 1-h daily walk resulted in significant decreases in systemic inflammation parameters. An important advantage of physical exercise is its potential to prevent metabolic side-effects of antipsychotics. Exercise also attenuates progressive grey matter loss in the early stages of schizophrenia and leads to an increase in hippocampal volume in patients. Whether exercise is effective in FEP or ARMS has not been tested, but may show particular promise in view of the absence of harmful side-effects.

Other non-pharmacological interventions consist of neuromodulation, using repetitive transcranial magnetic stimulation (rTMS) or transcranial direct current stimulation. Theoretically, these interventions can improve GABA-ergic inhibition with minimal side effects., Recent advances in spatial and temporal precision of these neuromodulation techniques allow for specific enhancement of neural synchrony in a particular brain area (for example, the dorsolateral prefrontal cortex), which can improve cognitive functions, such as working memory.,

Towards personalized medicine for patients with schizophrenia

Schizophrenia most likely develops from several different mechanisms, among which are increased DA synthesis, NMDAr hypofunction and increased proinflammatory status of the brain. Neuroimaging techniques may help to tailor treatments to the needs of individual patients. Given that the vast majority of FEP patients respond well to an antipsychotic agent, it does not seem worthwhile to use invasive and expensive PET scans for selection before a first medication trial. In the FEP patients who fail to respond to a first antipsychotic trial, however, further investigations may be valuable., MRS can be performed on most clinical magnetic resonance imaging scanners. Both the peak in glx observed during ARMS and FEP and the subsequent decrease observed in more chronic stages of the illness could be targeted with glutamatergic drugs. Likewise, decreases in GABA could be compensated with selective GABA-agonists. Alternatively, hypofunction of the GABA-ergic interneurons could be compensated by increasing cortical inhibition with targeted neuromodulation. Increased proinflammatory status of the brain, in particular increased microglia cell activation, can be detected with PET scans using the PK11195 tracer, but this is an invasive and expensive technique. As increased proinflammatory status may not be restricted to the brain, but may be systemic in a subset of patients with schizophrenia, measurements of proinflammatory cytokines in peripheral blood, such as the IL-1 receptor antagonist, IL-6 and sIL-2R could provide a simple screening method to select patients for augmentation with antiinflammatory drugs., Another approach could be to measure the concentration of C-reactive protein, which is a general reflection of heightened (native and adaptive) immune activity,, but also of metabolic syndrome, stress and even smoking.

Conclusion

At the time of first psychotic symptoms, neurobiological processes underlying schizophrenia have already been ongoing for many years. Although increased DA synthesis may be the final common pathway to psychosis, hypofunction of the NMDAr, associated decreased GABA-ergic signalling and increased proinflammatory status of the brain may be important mechanisms underlying cognitive dysfunction. The contribution of these pathophysiological pathways to the clinical picture of schizophrenia most likely varies per individual. If we aim to intervene before the window of opportunity is closed and deviations in the brain have become hard-wired, it will be key to include cognitive deterioration in the diagnosis of schizophrenia instead of postponing diagnosis until the onset of psychotic symptoms many years later. Meanwhile, effective interventions, with high numbers-needed-to-harm, should be considered for at-risk groups.

References 225

  1. 1.

    Kahn RS Keefe RS Schizophrenia is a cognitive illness: time for a change in focusJAMA Psychiatry2013 7011071112

    Not in our library10.1001/jamapsychiatry.2013.155

  2. 2.

    Haijma SV Van Haren N Cahn W Koolschijn PC Hulshoff Pol HE Kahn RS Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjectsSchizophr Bull2013 3911291138

    Not in our library10.1093/schbul/sbs118

  3. 3.

    O'Rahilly R Müller F Human Embryology & TeratologyWiley-Liss: New York, NY, USA1992

    Not in our library

  4. 4.

    Sgouros S Hockley AD Goldin JH Wake MJ Natarajan K Intracranial volume change in craniosynostosisJ Neurosurg1999 91617625

    Not in our library10.3171/jns.1999.91.4.0617

  5. 5.

    Blakemore SJ Imaging brain development: the adolescent brainNeuroimage2012 61397406

    Not in our library10.1016/j.neuroimage.2011.11.080

  6. 6.

    Hulshoff Pol HE Kahn RS What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophreniaSchizophr Bull2008 34354366

    Not in our library10.1093/schbul/sbm168

  7. 7.

    Hulshoff Pol HE Brans RG van Haren NE Schnack HG Langen M Baaré WF Gray and white matter volume abnormalities in monozygotic and same-gender dizygotic twins discordant for schizophreniaBiol Psychiatry2004 55126130

    Not in our library10.1016/s0006-3223(03)00728-5

  8. 8.

    Cahn W van Haren NE Hulshoff Pol HE Schnack HG Caspers E Laponder DA Brain volume changes in the first year of illness and 5-year outcome of schizophreniaBr J Psychiatry2006 189381382

    Not in our library10.1192/bjp.bp.105.015701

  9. 9.

    van Haren NE Cahn W Hulshoff Pol HE Kahn RS Confounders of excessive brain volume loss in schizophreniaNeurosci Biobehav Rev2013 3724182423

    Not in our library10.1016/j.neubiorev.2012.09.006

  10. 10.

    van Haren NE Schnack HG Cahn W van den Heuvel MP Lepage C Collins L Changes in cortical thickness during the course of illness in schizophreniaArch Gen Psychiatry2011 68871880

    Not in our library10.1001/archgenpsychiatry.2011.88

  11. 11.

    Ho BC Andreasen NC Ziebell S Pierson R Magnotta V Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophreniaArch Gen Psychiatry2011 68128137

    Not in our library10.1001/archgenpsychiatry.2010.199

  12. 12.

    Andreasen NC Liu D Ziebell S Vora A Ho BC Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI studyAm J Psychiatry2013 170609615

    Not in our library10.1176/appi.ajp.2013.12050674

  13. 13.

    Mandl RC Rais M van Baal GC van Haren NE Cahn W Kahn RS Altered white matter connectivity in never-medicated patients with schizophreniaHum Brain Mapp2013 3423532365

    Not in our library10.1002/hbm.22075

  14. 14.
    White matter integrity as a predictor of response to treatment in first episode psychosis · 2013
    No notice
  15. 15.

    Kuswanto CN Teh I Lee TS Sim K Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic reviewClin Psychopharmacol Neurosci2012 101324

    Not in our library10.9758/cpn.2012.10.1.13

  16. 16.

    Radua J Borgwardt S Crescini A Mataix-Cols D Meyer-Lindenberg A McGuire PK Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medicationNeurosci Biobehav Rev2012 3623252333

    Not in our library10.1016/j.neubiorev.2012.07.012

  17. 17.

    Vita A De Peri L Deste G Sacchetti E Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studiesTransl Psychiatry2012 2e190

    Not in our library10.1038/tp.2012.116

  18. 18.

    van Haren NE Cahn W Hulshoff Pol HE Kahn RS The course of brain abnormalities in schizophrenia: can we slow the progressionJ Psychopharmacol2012 26814

    Not in our library10.1177/0269881111408964

  19. 19.

    van Haren NE Cahn W Hulshoff Pol HE Kahn RS Schizophrenia as a progressive brain diseaseEur Psychiatry2008 23245254

    Not in our library10.1016/j.eurpsy.2007.10.013

  20. 20.

    Hulshoff Pol HE Kahn RS What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophreniaSchizophr Bull.2008 34354366

    Not in our library10.1093/schbul/sbm168

  21. 21.

    Steen RG Mull C McClure R Hamer RM Lieberman JA Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studiesBr J Psychiatry2006 188510518

    Not in our library10.1192/bjp.188.6.510

  22. 22.

    Wang Q Cheung C Deng W Li M Huang C Ma X White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatmentPsychol Med2013 4323012309

    Not in our library10.1017/s0033291713000238

  23. 23.

    Friedrich VL Jr Byne W Buitron C Perl DP Davis KL Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophreniaBiol Psychiatry2003 5310751085

    Not in our library10.1016/s0006-3223(03)00237-3

  24. 24.

    Schmitt A Steyskal C Bernstein HG Schneider-Axmann T Parlapani E Schaeffer EL Stereologic investigation of the posterior part of the hippocampus in schizophreniaActa Neuropathol2009 117395407

    Not in our library10.1007/s00401-008-0430-y

  25. 25.

    Fusar-Poli P Deste G Smieskova R Barlati S Yung AR Howes O Cognitive functioning in prodromal psychosis: a meta-analysisArch Gen Psychiatry2012 69562571

    Not in our library10.1001/archgenpsychiatry.2011.1592

  26. 26.

    Gajwani R Patterson P Birchwood M Attachment: developmental pathways to affective dysregulation in young people at ultra-high risk of developing psychosisBr J Clin Psychol2013 52424437

    Not in our library10.1111/bjc.12027

  27. 27.

    Fusar-Poli P Nelson B Valmaggia L Yung AR McGuire PK Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosisSchizophr Bull2014 40120131

    Not in our library10.1093/schbul/sbs136

  28. 28.

    Simon AE Grädel M Cattapan-Ludewig K Gruber K Ballinari P Roth B Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcomeSchizophr Res2012 142108115

    Not in our library10.1016/j.schres.2012.09.004

  29. 29.

    Simon AE Borgwardt S Riecher-Rössler A Velthorst E de Haan L Fusar-Poli P Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosisPsychiatry Res2013 209266272

    Not in our library10.1016/j.psychres.2013.03.004

  30. 30.

    Wood SJ Reniers RL Heinze K Neuroimaging findings in the at-risk mental state: a review of recent literatureCan J Psychiatry2013 581318

    Not in our library10.1177/070674371305800104

  31. 31.

    Mechelli A Riecher-Rössler A Meisenzahl EM Tognin S Wood SJ Borgwardt SJ Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter studyArch Gen Psychiatry2011 68489495

    Not in our library10.1001/archgenpsychiatry.2011.42

  32. 32.

    Samartzis L Dima D Fusar-Poli P Kyriakopoulos M White matter alterations in early stages of schizophrenia: a systematic review of diffusion tensor imaging studiesJ Neuroimaging2014 24101110

    Not in our library10.1111/j.1552-6569.2012.00779.x

  33. 33.

    Karlsgodt KH Niendam TA Bearden CE Cannon TD White matter integrity and prediction of social and role functioning in subjects at ultra-high risk for psychosisBiol Psychiatry2009 66562569

    Not in our library10.1016/j.biopsych.2009.03.013

  34. 34.

    Niendam TA Bearden CE Johnson JK McKinley M Loewy R O'Brien M Neurocognitive performance and functional disability in the psychosis prodromeSchizophr Res2006 84100111

    Not in our library10.1016/j.schres.2006.02.005

  35. 35.

    Lin A Wood SJ Nelson B Brewer WJ Spiliotacopoulos D Bruxner A Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosisSchizophr Res2011 13217

    Not in our library10.1016/j.schres.2011.06.014

  36. 36.

    van Oel CJ Sitskoorn MM Cremer MP Kahn RS School performance as a premorbid marker for schizophrenia: a twin studySchizophr Bull2002 28401414

    Not in our library10.1093/oxfordjournals.schbul.a006949

  37. 37.

    Howes OD Montgomery AJ Asselin MC Murray RM Valli I Tabraham P Elevated striatal dopamine function linked to prodromal signs of schizophreniaArch Gen Psychiatry2009 661320

    Not in our library10.1001/archgenpsychiatry.2008.514

  38. 38.

    Howes OD Bose SK Turkheimer F Valli I Egerton A Valmaggia LR Dopamine synthesis capacity before onset of psychosis: a prospective [18F]- DOPA PET imaging studyAm J Psychiatry2011 16813111317

    Not in our library10.1176/appi.ajp.2011.11010160

  39. 39.

    Bonoldi I Howes OD The enduring centrality of dopamine in the pathophysiology of schizophrenia: in vivo evidence from the prodrome to the first psychotic episodeAdv Pharmacol2013 68199220

    Not in our library10.1016/b978-0-12-411512-5.00010-5

  40. 40.

    Howes OD Kapur S The dopamine hypothesis of schizophrenia: version III—the final common pathwaySchizophr Bull2009 35549562

    Not in our library10.1093/schbul/sbp006

  41. 41.

    Winton-Brown TT Fusar-Poli P Ungless MA Howes OD Dopaminergic basis of salience dysregulation in psychosisTrends Neurosci2014 378594

    Not in our library10.1016/j.tins.2013.11.003

  42. 42.

    Bach ME Simpson EH Kahn L Marshall JJ Kandel ER Kellendonk C Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learningProc Natl Acad Sci USA2008 1051602716032

    Not in our library10.1073/pnas.0807746105

  43. 43.

    Anticevic A Gancsos M Murray JD Repovs G Driesen NR Ennis DJ NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophreniaProc Natl Acad Sci USA2012 1091672016725

    Not in our library10.1073/pnas.1208494109

  44. 44.

    Schwartz TL Sachdeva S Stahl SM Genetic data supporting the NMDA glutamate receptor hypothesis for schizophreniaCurr Pharm Des2012 1815801592

    Not in our library10.2174/138161212799958594

  45. 45.

    Krystal JH Anand A Moghaddam B Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophreniaArch Gen Psychiatry2002 59663664

    Not in our library10.1001/archpsyc.59.7.663

  46. 46.
    NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia · 2013
    No notice
  47. 47.

    Harrison PJ Weinberger DR Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergenceMol Psychiatry2005 104068, image 5.

    Not in our library10.1038/sj.mp.4001558

  48. 48.

    Hahn CG Wang HY Cho DS Talbot K Gur RE Berrettini WH Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophreniaNat Med2006 12824828

    Not in our library10.1038/nm1418

  49. 49.

    Fromer M Pocklington AJ Kavanagh DH William HJ Dwyer S Gormley P De novo mutations in schizophrenia implicate synaptic networksNature2014 506179184

    Not in our library10.1038/nature12929

  50. 50.

    Wang M Yang Y Wang CJ Gamo NJ Jin LE Mazer JA NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortexNeuron2013 77736749

    Not in our library10.1016/j.neuron.2012.12.032

  51. 51.

    Samuelsson AM Jennische E Hansson HA Holmäng A Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learningAm J Physiol Regul Integr Comp Physiol2006 290R1345R1356

    Not in our library10.1152/ajpregu.00268.2005

  52. 52.

    El-Khodor BF Flores G Srivastava LK Boksa P Effects of birth insult and stress at adulthood on excitatory amino acid receptors in adult rat brainSynapse2004 54138146

    Not in our library10.1002/syn.20073

  53. 53.

    Kaur C Sivakumar V Ang LS Sundaresan A Hypoxic damage to the periventricular white matter in neonatal brain: role of vascular endothelial growth factor, nitric oxide and excitotoxicityJ Neurochem2006 9812001216

    Not in our library10.1111/j.1471-4159.2006.03964.x

  54. 54.

    Owen D Setiawan E Li A McCabe L Matthews SG Regulation of N-methyl-D- aspartate receptor subunit expression in the fetal guinea pig brainBiol Reprod2004 71676683

    Not in our library10.1095/biolreprod.104.027946

  55. 55.

    Feinberg I Schizophrenia: caused by a fault in programmed synaptic elimination during adolescenceJ Psychiatr Res1982–1983 17319334

    Not in our library10.1016/0022-3956(82)90038-3

  56. 56.

    Lewis DA Hashimoto T Volk DW Cortical inhibitory neurons and schizophreniaNat Rev Neurosci2005 6312324

    Not in our library10.1038/nrn1648

  57. 57.

    Curley AA Arion D Volk DW Asafu-Adjei JK Sampson AR Fish KN Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific featuresAm J Psychiatry2011 168921929

    Not in our library10.1176/appi.ajp.2011.11010052

  58. 58.

    Hyde TM Lipska BK Ali T Mathew SV Law AJ Metitiri OE Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophreniaJ Neurosci2011 311108811095

    Not in our library10.1523/jneurosci.1234-11.2011

  59. 59.

    Hoff AL Svetina C Shields G Stewart J DeLisi LE Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophreniaSchizophr Res2005 782734

    Not in our library10.1016/j.schres.2005.05.010

  60. 60.

    Floresco SB Todd CL Grace AA Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neuronsJ Neurosci2001 2149154922

    Not in our library10.1523/jneurosci.21-13-04915.2001

  61. 61.

    Adell A Jiménez-Sánchez L López-Gil X Romón T Is the acute NMDA receptor hypofunction a valid model of schizophreniaSchizophr Bull2012 38914

    Not in our library10.1093/schbul/sbr133

  62. 62.

    Rowland LM Kontson K West J Edden RA Zhu H Wijtenburg SA In vivo measurements of glutamate, GABA, and NAAG in schizophreniaSchizophr Bull2013 3910961104

    Not in our library10.1093/schbul/sbs092

  63. 63.

    Rowland LM Bustillo JR Mullins PG Jung RE Lenroot R Landgraf E Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS studyAm J Psychiatry2005 162394396

    Not in our library10.1176/appi.ajp.162.2.394

  64. 64.

    Tibbo P Hanstock C Valiakalayil A Allen P 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophreniaAm J Psychiatry2004 16111161118

    Not in our library10.1176/appi.ajp.161.6.1116

  65. 65.

    Keshavan MS Dick RM Diwadkar VA Montrose DM Prasad KM Stanley JA Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy studySchizophr Res2009 1158893

    Not in our library10.1016/j.schres.2009.08.012

  66. 66.

    de la Fuente-Sandoval C León-Ortiz P Favila R Stephano S Mamo D Ramírez- Bermúdez J Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosisNeuropsychopharmacology2011 3617811791

    Not in our library10.1038/npp.2011.65

  67. 67.

    de la Fuente-Sandoval C León-Ortiz P Azcárraga M Favila R Stephano S Graff- Guerrero A Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging studyInt J Neuropsychopharmacol2013 16471475

    Not in our library10.1017/s1461145712000314

  68. 68.

    Tandon N Bolo NR Sanghavi K Mathew IT Francis AN Stanley JA Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopySchizophr Res2013 1485966

    Not in our library10.1016/j.schres.2013.05.024

  69. 69.

    Stone JM Day F Tsagaraki H Valli I McLean MA Lythgoe DJ OASIS. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volumeBiol Psychiatry2009 66533539

    Not in our library10.1016/j.biopsych.2009.05.006

  70. 70.

    Fusar-Poli P Broome MR Matthiasson P Woolley JB Mechelli A Johns LC Prefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosisSchizophr Bull2011 37189198

    Not in our library10.1093/schbul/sbp074

  71. 71.

    Yoo SY Yeon S Choi CH Kang DH Lee JM Shin NY Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamusSchizophr Res2009 1118693

    Not in our library10.1016/j.schres.2009.03.036

  72. 72.

    Natsubori T Inoue H Abe O Takano Y Iwashiro N Aoki Y Reduced frontal Glutamate + Glutamine and N-Acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophreniaSchizophr Bulladvance online publication, 10 September 2013; PMID: 24023251 (e-pub ahead of print).

    Not in our library10.1093/schbul/sbt124

  73. 73.

    Bartha R Williamson PC Drost DJ Malla A Carr TJ Cortese L Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopyArch Gen Psychiatry1997 54959965

    Not in our library10.1001/archpsyc.1997.01830220085012

  74. 74.

    Théberge J Jensen JE Rowland LM Regarding "Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study”Biol Psychiatry2007 6112181219

    Not in our library10.1016/j.biopsych.2006.05.037

  75. 75.

    Bustillo JR Rowland LM Mullins P Jung R Chen H Qualls C 1H-MRS at 4 tesla in minimally treated early schizophreniaMol Psychiatry.2010 15629636

    Not in our library10.1038/mp.2009.121

  76. 76.

    Stanley JA Williamson PC Drost DJ Rylett RJ Carr TJ Malla A An in vivo proton magnetic resonance spectroscopy study of schizophrenia patientsSchizophr Bull1996 22597609

    Not in our library10.1093/schbul/22.4.597

  77. 77.

    Wood SJ Yücel M Wellard RM Harrison BJ Clarke K Fornito A Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 TSchizophr Res2007 94328331

    Not in our library10.1016/j.schres.2007.05.008

  78. 78.

    Galińska B Szulc A Tarasów E Kubas B Dzienis W Czernikiewicz A Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophreniaMed Sci Monit2009 15CR82CR88

    Not in our library

  79. 79.

    Bustillo JR Chen H Gasparovic C Mullins P Caprihan A Qualls C Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 TeslaBiol Psychiatry2011 691927

    Not in our library10.1016/j.biopsych.2010.08.024

  80. 80.

    Marsman A van den Heuvel MP Klomp DW Kahn RS Luijten PR Hulshoff Pol HE Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studiesSchizophr Bull2013 39120129

    Not in our library10.1093/schbul/sbr069

  81. 81.

    Bustillo JR Chen H Jones T Lemke N Abbott C Qualls C Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 TJAMA Psychiatry2014 71265272

    Not in our library10.1001/jamapsychiatry.2013.3939

  82. 82.

    Goto N Yoshimura R Moriya J Kakeda S Ueda N Ikenouchi-Sugita A Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS studySchizophr Res2009 112192193

    Not in our library10.1016/j.schres.2009.04.026

  83. 83.

    Yoon JH Maddock RJ Rokem A Silver MA Minzenberg MJ Ragland JD GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppressionJ Neurosci2010 3037773781

    Not in our library10.1523/jneurosci.6158-09.2010

  84. 84.

    Tayoshi S Nakataki M Sumitani S Taniguchi K Shibuya-Tayoshi S Numata S GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy studySchizophr Res2010 1178391

    Not in our library10.1016/j.schres.2009.11.011

  85. 85.

    Stevens JR Neuropathology of schizophreniaArch Gen Psychiatry1982 3911311139

    Not in our library10.1001/archpsyc.1982.04290100011003

  86. 86.

    de Jong S van Eijk KR Zeegers DW Strengman E Janson E Veldink JH PGC Schizophrenia (GWAS)Consortium. Expression QTL analysis of top loci from GWAS meta-analysis highlights additional schizophrenia candidate genesEur J Hum Genet2012 2010041008

    Not in our library10.1038/ejhg.2012.38

  87. 87.

    Stefansson H Ophoff RA Steinberg S Andreassen OA Cichon S Rujescu D Common variants conferring risk of schizophreniaNature2009 460744747

    Not in our library10.1038/nature08186

  88. 88.

    Corvin A Morris DW Genome-wide association Studies: Findings at the major histo- compatibility complex locus in psychosisBiol Psychiatry2014 75276283

    Not in our library10.1016/j.biopsych.2013.09.018

  89. 89.

    McAllister AK Major Histocompatibility Complex I in Brain Development and SchizophreniaBiol Psychiatry2014 75262268

    Not in our library10.1016/j.biopsych.2013.10.003

  90. 90.

    Huh GS Boulanger LM Du H Riquelme PA Brotz TM Shatz CJ Functional requirement for class I MHC in CNS development and plasticityScience2000 29021552159

    Not in our library10.1126/science.290.5499.2155

  91. 91.

    Shatz CJ MHC class I: an unexpected role in neuronal plasticityNeuron2009 644045

    Not in our library10.1016/j.neuron.2009.09.044

  92. 92.

    Canetta SE Brown AS Prenatal infection, maternal immune activation, and risk for schizophreniaTransl Neurosci2012 3320327

    Not in our library10.2478/s13380-012-0045-6

  93. 93.

    Benros ME Nielsen PR Nordentoft M Eaton WW Dalton SO Mortensen PB Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register studyAm J Psychiatry2011 16813031310

    Not in our library10.1176/appi.ajp.2011.11030516

  94. 94.

    Steiner J Walter M Glanz W Sarnyai Z Bernstein HG Vielhaber S Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitisJAMA Psychiatry2013 70271278

    Not in our library10.1001/2013.jamapsychiatry.86

  95. 95.

    Hagberg H Gressens P Mallard C Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adultsAnn Neurol.2012 71444457

    Not in our library10.1002/ana.22620

  96. 96.

    van Berckel BN Bossong MG Boellaard R Kloet R Schuitemaker A Caspers E Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography studyBiol Psychiatry2008 64820822

    Not in our library10.1016/j.biopsych.2008.04.025

  97. 97.

    Doorduin J de Vries EF Willemsen AT de Groot JC Dierckx RA Klein HC Neuroinflammation in schizophrenia-related psychosis: a PET studyJ Nucl Med2009 5018011807

    Not in our library10.2967/jnumed.109.066647

  98. 98.

    Takano A Arakawa R Ito H Tateno A Takahashi H Matsumoto R Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106Int J Neuropsychopharmacol2010 13943950

    Not in our library10.1017/s1461145710000313

  99. 99.

    Chauveau F Van Camp N Dollé F Kuhnast B Hinnen F Damont A Comparative evaluation of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat model of acute neuroinflammationJ Nucl Med2009 50468476

    Not in our library10.2967/jnumed.108.058669

  100. 100.

    Monji A Kato T Kanba S Cytokines and schizophrenia: Microglia hypothesis of schizophreniaPsychiatry Clin Neurosci2009 63257265

    Not in our library10.1111/j.1440-1819.2009.01945.x

  101. 101.

    Narayan S Tang B Head SR Gilmartin TJ Sutcliffe JG Dean B Molecular profiles of schizophrenia in the CNS at different stages of illnessBrain Res2008 1239235248

    Not in our library10.1016/j.brainres.2008.08.023

  102. 102.

    Miller BJ Buckley P Seabolt W Mellor A Kirkpatrick B Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effectsBiol Psychiatry2011 70663671

    Not in our library10.1016/j.biopsych.2011.04.013

  103. 103.

    Feigenson KA Kusnecov AW Silverstein SM Inflammation and the two-hit hypothesis of schizophreniaNeurosci Biobehav Rev2014 387293

    Not in our library10.1016/j.neubiorev.2013.11.006

  104. 104.

    Papadia S Soriano FX Leveille F Martel MA Dakin KA Hansen HH Synaptic NMDA receptor activity boosts intrinsic antioxidant defensesNat Neurosci2008 11476487

    Not in our library10.1038/nn2071

  105. 105.

    Smith SE Li J Garbett K Mirnics K Patterson PH Maternal immune activation alters fetal brain development through interleukin-6J Neurosci2007 271069510702

    Not in our library10.1523/jneurosci.2178-07.2007

  106. 106.

    Behrens MM Ali SS Dugan LL Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophreniaJ Neurosci2008 281395713966

    Not in our library10.1523/jneurosci.4457-08.2008

  107. 107.

    Muller N Schwarz M Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmissionNeurotox Res2006 10131148

    Not in our library10.1007/bf03033242

  108. 108.

    Mayer ML Westbrook GL Vyklický L Jr Sites of antagonist action on N-methyl-D- aspartic acid receptors studied using fluctuation analysis and a rapid perfusion techniqueJ Neurophysiol1988 60645663

    Not in our library10.1152/jn.1988.60.2.645

  109. 109.

    Coyle JT Nitric oxide and symptom reduction in schizophreniaJAMA Psychiatry2013 70664665

    Not in our library10.1001/jamapsychiatry.2013.210

  110. 110.

    Meyer U Feldon J Neural basis of psychosis-related behaviour in the infection model of schizophreniaBehav Brain Res2009 204322334

    Not in our library10.1016/j.bbr.2008.12.022

  111. 111.

    Pasternak O Westin CF Bouix S Seidman LJ Goldstein JM Woo TU Excessive extracellular volume reveals a neurodegenerative pattern in schizophrenia onsetJ Neurosci2012 321736517372

    Not in our library10.1523/jneurosci.2904-12.2012

  112. 112.

    Egerton A Fusar-Poli P Stone JM Glutamate and psychosis riskCurr Pharm Des2012 18466478

    Not in our library10.2174/138161212799316244

  113. 113.

    Demjaha A Murray RM McGuire PK Kapur S Howes OD Dopamine synthesis capacity in patients with treatment-resistant schizophreniaAm J Psychiatry2012 16912031210

    Not in our library10.1176/appi.ajp.2012.12010144

  114. 114.

    Fillman SG Cloonan N Miller LC Weickert CS Markers of inflammation in the prefrontal cortex of individuals with schizophreniaMol Psychiatry2013 18133

    Not in our library10.1038/mp.2012.199

  115. 115.

    Kato T Monji A Hashioka S Kanba S Risperidone significantly inhibits interferon- gamma-induced microglial activation in vitroSchizophr Res2007 92108115

    Not in our library10.1016/j.schres.2007.01.019

  116. 116.

    Kato TA Monji A Mizoguchi Y Hashioka S Horikawa H Seki Y Kasai M Utsumi H Kanba S Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophreniaMini Rev Med Chem2011 11565574

    Not in our library10.2174/138955711795906941

  117. 117.

    Zheng LT Hwang J Ock J Lee MG Lee WH Suk K The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide productionJ Neurochem2008 10712251235

    Not in our library10.1111/j.1471-4159.2008.05675.x

  118. 118.

    Kahn RS Fleischhacker WW Boter H Davidson M Vergouwe Y Keet IP Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet2008 37110851097

    Not in our library10.1016/s0140-6736(08)60486-9

  119. 119.

    Robinson D First-episode schizophreniaCNS Spectr2010 1547

    Not in our library10.1017/s1092852900027681

  120. 120.

    Robinson DG Woerner MG Alvir JM Geisler S Koreen A Sheitman B Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorderAm J Psychiatry1999 156544549

    Not in our library10.1176/ajp.156.4.544

  121. 121.

    Agid O Arenovich T Sajeev G Zipursky RB Kapur S Foussias G An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysisJ Clin Psychiatry2011 7214391444

    Not in our library10.4088/jcp.09m05785yel

  122. 122.

    Singh SP Singh V Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaCNS Drugs2011 25859885

    Not in our library10.2165/11586650-000000000-00000

  123. 123.

    Heresco-Levy U Javitt DC Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysisSchizophr Res2004 668996

    Not in our library10.1016/s0920-9964(03)00129-4

  124. 124.

    Hashimoto K Malchow B Falkai P Schmitt A Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disordersEur Arch Psychiatry Clin Neurosci2013 263367377

    Not in our library10.1007/s00406-013-0399-y

  125. 125.

    Goff DC Lamberti JS Leon AC Green MF Miller AL Patel J A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophreniaNeuropsychopharmacology2008 33465472

    Not in our library10.1038/sj.npp.1301444

  126. 126.

    Lane HY Liu YC Huang CL Chang YC Liau CH Perng CH Sarcosine (Nmethylglycine) treatment for acute schizophrenia: a randomized, double-blind studyBiol Psychiatry2008 63912

    Not in our library10.1016/j.biopsych.2007.04.038

  127. 127.

    Patil ST Zhang L Martenyi F Lowe SL Jackson KA Andregv BV Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNat Med2007 1311021107

    Not in our library10.1038/nm1632

  128. 128.

    Kinon BJ Zhang L Millen BA Osuntokun OO Williams JE Kollack-Walker S A multicenter, inpatient, phase 2, double-blind, placebocontrolled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophreniaJ Clin Psychopharmacol2011 31349355

    Not in our library10.1097/jcp.0b013e318218dcd5

  129. 129.

    Gill KM Grace AA The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophreniaCurr Pharm Desadvance online publication, 15 December 2013 (e-pub ahead of print).

    Not in our library10.2174/1381612819666131216114612

  130. 130.

    Vinkers CH Mirza NR Olivier B Kahn RS The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipelineExpert Opin Investig Drugs2010 1912171233

    Not in our library10.1517/13543784.2010.513382

  131. 131.

    Insel TR Rethinking schizophreniaNature2010 468187193

    Not in our library10.1038/nature09552

  132. 132.

    Sommer IE van Westrhenen R Begemann MJ de Witte LD Leucht S Kahn RS Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An UpdateSchizophr Bull2014 40181191

    Not in our library10.1093/schbul/sbt139

  133. 133.

    Carmeli C Knyazeva MG Cuénod M Do KQ Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trialPLoS One2012 7e29341

    Not in our library10.1371/journal.pone.0029341

  134. 134.

    Lavoie S Murray MM Deppen P Knyazeva MG Berk M Boulat O Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patientsNeuropsychopharmacology2008 3321872199

    Not in our library10.1038/sj.npp.1301624

  135. 135.

    Amminger GP Schäfer MR Papageorgiou K Klier CM Cotton SM Harrigan SM Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trialArch Gen Psychiatry2010 67146154

    Not in our library10.1001/archgenpsychiatry.2009.192

  136. 136.

    Mossaheb N Schäfer MR Schlögelhofer M Klier CM Cotton SM McGorry PD Amminger GP Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effectiveSchizophr Res2013 148163167

    Not in our library10.1016/j.schres.2013.05.027

  137. 137.

    Berk M Malhi GS Gray LJ Dean OM The promise of N-acetylcysteine in neuropsychiatryTrends Pharmacol Sci2013 34167177

    Not in our library10.1016/j.tips.2013.01.001

  138. 138.

    Schmaal L Berk L Hulstijn KP Cousijn J Wiers RW van den Brink W Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot studyEur Addict Res2011 17211216

    Not in our library10.1159/000327682

  139. 139.

    Schneider ML Kwan BM Psychological need satisfaction, intrinsic motivation and affective response to exercise in adolescentsPsychol Sport Exerc2013 14776785

    Not in our library10.1016/j.psychsport.2013.04.005

  140. 140.

    Scheewe TW Backx FJ Takken T Jörg F van Strater AC Kroes AG Exercise therapy improves mental and physical health in schizophrenia: a randomised controlled trialActa Psychiatr Scand2013 127464473

    Not in our library10.1111/acps.12029

  141. 141.

    Radom-Aizik S Zaldivar FP Jr Haddad F Cooper DM Impact of brief exercise on circulating monocyte gene and microRNA expression: Implications for atherosclerotic vascular diseaseBrain Behav Immun2014 39121129

    Not in our library10.1016/j.bbi.2014.01.003

  142. 142.

    Di Raimondo D Tuttolomondo A Buttà C Casuccio A Giarrusso L Miceli G Metabolic and anti-inflammatory effects of a home-based programme of aerobic physical exerciseInt J Clin Pract2013 6712471253

    Not in our library10.1111/ijcp.12269

  143. 143.

    Abdel-Baki A Brazzini-Poisson V Marois F Letendre E Karelis AD Effects of aerobic interval training on metabolic complications and cardiorespiratory fitness in young adults with psychotic disorders: a pilot studySchizophr Res2013 149112115

    Not in our library10.1016/j.schres.2013.06.040

  144. 144.

    Scheewe TW van Haren NE Sarkisyan G Schnack HG Brouwer RM de Glint M Exercise therapy, cardiorespiratory fitness and their effect on brain volumes: a randomised controlled trial in patients with schizophrenia and healthy controlsEur Neuropsychopharmacol2013 23675685

    Not in our library10.1016/j.euroneuro.2012.08.008

  145. 145.

    Pajonk FG Wobrock T Gruber O Scherk H Berner D Kaizl I Hippocampal plasticity in response to exercise in schizophreniaArch Gen Psychiatry2010 67133143

    Not in our library10.1001/archgenpsychiatry.2009.193

  146. 146.

    Daskalakis ZJ Möller B Christensen BK Fitzgerald PB Gunraj C Chen R The effects of repetitive transcranial magnetic stimulation on cortical inhibition in healthy human subjectsExp Brain Res2006 174403412

    Not in our library10.1007/s00221-006-0472-0

  147. 147.

    de Jesus DR Favalli GP Hoppenbrouwers SS Barr MS Chen R Fitzgerald PB Determining optimal rTMS parameters through changes in cortical inhibitionClin Neurophysiol2013 12413091320

    Not in our library10.1016/j.clinph.2013.09.011

  148. 148.

    Luber B Kinnunen LH Rakitin BC Ellsasser R Stern Y Lisanby SH Facilitation of performance in a working memory task with rTMS stimulation of the precuneus: frequency- and time-dependent effectsBrain Res2007 1128120129

    Not in our library10.1016/j.brainres.2006.10.011

  149. 149.

    Luber B Steffener J Tucker A Habeck C Peterchev AV Deng ZD Extended remediation of sleep deprived-induced working memory deficits using fMRI-guided transcranial magnetic stimulationSleep2013 36857871

    Not in our library10.5665/sleep.2712

  150. 150.

    Potvin S Stip E Sepehry AA Gendron A Bah R Kouassi E Inflammatory cytokine alterations in schizophrenia: a systematic quantitative reviewBiol Psychiatry2008 63801808

    Not in our library10.1016/j.biopsych.2007.09.024

  151. 151.

    Zakharyan R Boyajyan A Inflammatory cytokine network in schizophreniaWorld J Biol Psychiatry2014 15174187

    Not in our library10.3109/15622975.2013.830774

  152. 152.

    Dickerson F Stallings C Origoni A Boronow J Yolken R C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophreniaSchizophr Res2007 93261265

    Not in our library10.1016/j.schres.2007.03.022

  153. 153.

    Dickerson F Stallings C Origoni A Vaughan C Khushalani S Yang S C-reactive protein is elevated in schizophreniaSchizophr Res2013 143198202

    Not in our library10.1016/j.schres.2012.10.041

  154. 154.

    Vuksan-Cusa B Sagud M Jakovljevic M Peles AM Jaksic N Mihaljevic S Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophreniaNord J Psychiatry2013 67320325

    Not in our library10.3109/08039488.2012.745601

  155. 155.

    Allen P Chaddock CA Howes OD Egerton A Seal ML Fusar-Poli P Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosisSchizophr Bull.2012 3810409

    Not in our library10.1093/schbul/sbr017

  156. 156.

    Bloemen OJN de Koning MB Gleich T Meijer J de Haan L Linszen DH Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosisEur Neuropsychopharmacol2013 23126132

    Not in our library10.1016/j.euroneuro.2012.04.015

  157. 157.

    Egerton A Chaddock CA Winton-Brown TT Bloomfield MAP Bhattacharyya S Allen P Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohortBiol Psychiatry2013 74106112

    Not in our library10.1016/j.biopsych.2012.11.017

  158. 158.

    Fusar-Poli P Howes OD Allen P Broome M Valli I Asselin MC Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging studyArch Gen Psychiatry2010 67683691

    Not in our library10.1001/archgenpsychiatry.2010.77

  159. 159.

    Fusar-Poli P Howes OD Allen P Broome M Valli I Asselin MC Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosisMol. Psychiatry2011 166775

    Not in our library10.1038/mp.2009.108

  160. 160.

    Hirvonen J van Erp TGM Huttunen J Aalto S Någren K Huttunen M Increased caudate dopamine D2 receptor availability as a genetic marker for schizophreniaArch Gen Psychiatry2005 62371378

    Not in our library10.1001/archpsyc.62.4.371

  161. 161.

    Howes O Bose S Turkheimer F Valli I Egerton A Stahl D Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET studyMol Psychiatry2011a 16885886

    Not in our library10.1038/mp.2011.20

  162. 162.

    Suridjan I Rusjan P Addington J Wilson AA Houle S Mizrahi R Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive taskJ Psychiatry Neurosci2013 3898106

    Not in our library10.1503/jpn.110181

  163. 163.

    Abi-Dargham A Mawlawi O Lombardo I Gil R Martinez D Huang Y Prefrontal dopamine D1 receptors and working memory in schizophreniaJ Neurosci2002 2237083719

    Not in our library10.1523/jneurosci.22-09-03708.2002

  164. 164.

    Abi-Dargham A Xu X Thompson JL Gil R Kegeles LS Urban N Increased prefrontal cortical D 1 receptors in drug naive patients with schizophrenia: a PET study with [11 C]NNC112J Psychopharmacol (Oxford)2012 26794805

    Not in our library10.1177/0269881111409265

  165. 165.

    Buchsbaum MS Christian BT Lehrer DS Narayanan TK Shi B Mantil J D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophreniaSchizophr Res2006 85232244

    Not in our library10.1016/j.schres.2006.03.042

  166. 166.

    Corripio I Pérez V Catafau AM Mena E Carrió I Alvarez E Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosisNeuroimage2006 29662666

    Not in our library10.1016/j.neuroimage.2005.07.038

  167. 167.

    Corripio I Escartí MJ Portella MJ Pérez V Grasa E Sauras RB Density of striatal D2 receptors in untreated first-episode psychosis: an I123-IBZM SPECT studyEur Neuropsychopharmacol2011 21861866

    Not in our library10.1016/j.euroneuro.2011.03.004

  168. 168.

    Glenthoj BY Mackeprang T Svarer C Rasmussen H Pinborg LH Friberg L Frontal Dopamine D2/3 Receptor Binding in Drug-Naive First-Episode Schizophrenic Patients Correlates with Positive Psychotic Symptoms and GenderBiological Psychiatry2006 60621629

    Not in our library10.1016/j.biopsych.2006.01.010

  169. 169.

    Graff-Guerrero A Mamo D Shammi CM Mizrahi R Marcon H Barsoum P The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNOArch Gen Psychiatry2009a 66606615

    Not in our library10.1001/archgenpsychiatry.2009.43

  170. 170.

    Graff-Guerrero A Mizrahi R Agid O Marcon H Barsoum P Rusjan P The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET studyNeuropsychopharmacology2009b 3410781086

    Not in our library10.1038/npp.2008.199

  171. 171.

    Hietala J Syvälahti E Vuorio K Räkköläinen V Bergman J Haaparanta M Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patientsLancet1995 34611301131

    Not in our library10.1016/s0140-6736(95)91801-9

  172. 172.

    Hietala J Syvälahti E Vilkman H Vuorio K Räkköläinen V Bergman J Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophreniaSchizophr Res1999 354150

    Not in our library10.1016/s0920-9964(98)00113-3

  173. 173.

    Hsiao MC Lin KJ Liu CY Tzen KY Yen TC Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1Schizophr Res2003 653946

    Not in our library10.1016/s0920-9964(03)00006-9

  174. 174.

    Karlsson P Farde L Halldin C Sedvall G PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophreniaAm J Psychiatry2002 159761767

    Not in our library10.1176/appi.ajp.159.5.761

  175. 175.

    Laakso A Vilkman H Alakare B Haaparanta M Bergman J Solin O Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomographyAm J Psychiatry2000 157269271

    Not in our library10.1176/appi.ajp.157.2.269

  176. 176.

    Lavalaye J Linszen DH Booij J Dingemans PM Reneman L Habraken JB Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECTSchizophr Res2001 475967

    Not in our library10.1016/s0920-9964(00)00023-2

  177. 177.

    Lehrer DS Christian BT Kirbas C Chiang M Sidhu S Short H 18F-fallypride binding potential in patients with schizophrenia compared to healthy controlsSchizophr Res2010 1224352

    Not in our library10.1016/j.schres.2010.03.043

  178. 178.

    Lindström LH Gefvert O Hagberg G Lundberg T Bergström M Hartvig P Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PETBiol Psychiatry1999 46681688

    Not in our library10.1016/s0006-3223(99)00109-2

  179. 179.

    Mateos JJ Lomeña F Parellada E Font M Fernandez E Pavia J Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonismPsychopharmacology (Berl)2005 181401406

    Not in our library10.1007/s00213-005-2250-2

  180. 180.

    Mateos JJ Lomeña F Parellada E Font M Fernández E Pavia J Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidoneRev Esp Med Nucl2006 25159165

    Not in our library10.1157/13088411

  181. 181.

    Mateos JJ Lomeña F Parellada E Mireia F Fernandez-Egea E Pavia J Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness traitPsychopharmacology (Berl)191805811

    Not in our library10.1007/s00213-006-0570-5

  182. 182.

    Nozaki S Kato M Takano H Ito H Takahashi H Arakawa R Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PETSchizophr Res2009 1087884

    Not in our library10.1016/j.schres.2008.11.006

  183. 183.

    Safont G Corripio I Escartí MJ Portella MJ Pérez V Ferrer M Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: an in vivo SPECT studySchizophr Res2011 129169171

    Not in our library10.1016/j.schres.2011.03.012

  184. 184.

    Schmitt GJE Meisenzahl EM Frodl T La Fougère C Hahn K Möller HJ The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1J Psychopharmacol (Oxford)2005 19488493

    Not in our library10.1177/0269881105056530

  185. 185.

    Schmitt GJE Frodl T Dresel S la Fougère C Bottlender R Koutsouleris N Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patientsEur Arch Psychiatry Clin Neurosci2006 256115121

    Not in our library10.1007/s00406-005-0618-2

  186. 186.

    Schmitt GJE la Fougère C Dresel S Frodl T Hahn K Möller HJ Dual-isotope SPECT imaging of striatal dopamine: first episode, drug naïve schizophrenic patientsSchizophr Res2008 101133141

    Not in our library10.1016/j.schres.2007.11.010

  187. 187.

    Schmitt GJE Meisenzahl EM Frodl T La Fougère C Hahn K Möller HJ Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [(123)I]IBZM SPECTPsychiatry Res2009 173183189

    Not in our library10.1016/j.pscychresns.2008.11.001

  188. 188.

    Schmitt GJE Dresel S Frodl T la Fougère C Boerner R Hahn K Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patientsEur Arch Psychiatry Clin Neurosci2012 262183191

    Not in our library10.1007/s00406-011-0269-4

  189. 189.

    Talvik M Nordström AL Olsson H Halldin C Farde L Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457Int. J Neuropsychopharmacol2003 6361370

    Not in our library10.1017/s1461145703003699

  190. 190.

    Talvik M Nordström AL Okubo Y Olsson H Borg J Halldin C Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomographyPsychiatry Res2006 148165173

    Not in our library10.1016/j.pscychresns.2006.05.009

  191. 191.

    Yang YK Yu L Yeh TL Chiu NT Chen PS Lee IH Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT studyAm J Psychiatry2004 16114961498

    Not in our library10.1176/appi.ajp.161.8.1496

  192. 192.

    Yasuno F Suhara T Okubo Y Sudo Y Inoue M Ichimiya T Low dopamine d(2) receptor binding in subregions of the thalamus in schizophreniaAm J Psychiatry2004 16110161022

    Not in our library10.1176/appi.ajp.161.6.1016

  193. 193.

    Bloemen OJN Gleich T de Koning MB da Silva Alvis F de Haan L Linszen DH Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosisBiol Psychiatry2011 70e12, author reply e3.

    Not in our library10.1016/j.biopsych.2010.11.030

  194. 194.

    Fusar-Poli P Stone JM Broome MR Valli I Mechelli A McLean MA Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosisArch. Gen. Psychiatry2011 68881890

    Not in our library10.1001/archgenpsychiatry.2011.46

  195. 195.

    Purdon SE Valiakalayil A Hanstock CC Seres P Tibbo P Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophreniaSchizophr Res2008 99218224

    Not in our library10.1016/j.schres.2007.11.028

  196. 196.

    Valli I Stone J Mechelli A Bhattacharyya S Raffin M Allen P Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosisBiol Psychiatry2011 699799

    Not in our library10.1016/j.biopsych.2010.08.033

  197. 197.

    Bartha R al-Semaan YM Williamson PC Drost DJ Malla AK Carr TJ A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patientsBiol Psychiatry1999 4514031411

    Not in our library10.1016/s0006-3223(99)00007-4

  198. 198.

    De la Fuente-Sandoval C León-Ortiz P Azcárraga M Stephano S Favila R Díaz-Galvis L Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy studyJAMA Psychiatry2013 7010571066

    Not in our library10.1001/jamapsychiatry.2013.289

  199. 199.

    Ohrmann P Siegmund A Suslow T Spitzberg K Kersting A Arolt V Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy studySchizophr Res2005 73153157

    Not in our library10.1016/j.schres.2004.08.021

  200. 200.

    Ohrmann P Siegmund A Suslow T Pedersen A Spitzberg K Kersting A Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy studyJ Psychiatr Res2007 41625634

    Not in our library10.1016/j.jpsychires.2006.07.002

  201. 201.

    Olbrich HM Valerius G Rüsch N Buchert M Thiel T Hennig J Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy studyWorld J Biol Psychiatry2008 95963

    Not in our library10.1080/15622970701227811

  202. 202.

    Théberge J Bartha R Drost DJ Menon RS Malla A Takhar J Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteersAm J Psychiatry2002 15919441946

    Not in our library10.1176/appi.ajp.159.11.1944

  203. 203.

    Théberge J Williamson KE Aoyama N Drost DJ Manchanda R Malla AK Longitudinal grey-matter and glutamatergic losses in first-episode schizophreniaBr J Psychiatry2007 191325334

    Not in our library10.1192/bjp.bp.106.033670

  204. 204.

    Wood SJ Berger GE Wellard RM Proffitt T McConchie M Velakoulis D A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosisSchizophr Res2008 102163170

    Not in our library10.1016/j.schres.2008.03.012

  205. 205.

    Arnold SE Trojanowski JQ Gur RE Blackwell P Han LY Choi C Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophreniaArch. Gen. Psychiatry1998 55225232

    Not in our library10.1001/archpsyc.55.3.225

  206. 206.

    Bayer TA Buslei R Havas L Falkai P Evidence for activation of microglia in patients with psychiatric illnessesNeurosci. Lett1999 271126128

    Not in our library10.1016/s0304-3940(99)00545-5

  207. 207.

    Bruton CJ Crow TJ Frith CD Johnstone EC Owens DG Roberts GW Schizophrenia and the brain: a prospective clinico-neuropathological studyPsychol Med1990 20285304

    Not in our library10.1017/s0033291700017608

  208. 208.

    Busse S Busse M Schiltz K Bielau H Gos T Brisch R Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterationsBrain Behav Immun2012 2612731279

    Not in our library10.1016/j.bbi.2012.08.005

  209. 209.

    Falke E Han LY Arnold SE Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophreniaPsychiatry Res2000 93103110

    Not in our library10.1016/s0165-1781(00)00104-9

  210. 210.

    Fillman SG Cloonan N Catts VS Miller LC Wong J McCrossin T Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophreniaMol Psychiatry2013 18206214

    Not in our library10.1038/mp.2012.110

  211. 211.

    Fisman M The brain stem in psychosisBr J Psychiatry1975 126414422

    Not in our library10.1192/bjp.126.5.414

  212. 212.

    Kurumaji A Wakai T Toru M Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenicsJ Neural Transm1997 10413611370

    Not in our library10.1007/bf01294737

  213. 213.

    Nasrallah HA McCalley-Whitters M Bigelow LB Rauscher FP A histological study of the corpus callosum in chronic schizophreniaPsychiatry Res1983 8251260

    Not in our library10.1016/0165-1781(83)90013-6

  214. 214.

    Radewicz K Garey LJ Gentleman SM Reynolds R Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenicsJ Neuropathol Exp Neurol2000 59137150

    Not in our library10.1093/jnen/59.2.137

  215. 215.

    Rao JS Kim H-W Harry GJ Rapoport SI Reese EA Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patientsSchizophr Res2013 1472431

    Not in our library10.1016/j.schres.2013.02.017

  216. 216.

    Roberts GW Colter N Lofthouse R Bogerts B Zech M Crow TJ Gliosis in schizophrenia: a surveyBiol Psychiatry1986 2110431050

    Not in our library10.1016/0006-3223(86)90285-4

  217. 217.

    Roberts GW Colter N Lofthouse R Johnstone EC Crow TJ Is there gliosis in schizophrenia? Investigation of the temporal lobeBiol Psychiatry1987 2214591468

    Not in our library10.1016/0006-3223(87)90104-1

  218. 218.

    Steiner J Mawrin C Ziegeler A Bielau H Ullrich O Bernstein H-G Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralizationActa Neuropathol2006 112305316

    Not in our library10.1007/s00401-006-0090-8

  219. 219.

    Steiner J Bernstein H-G Bielau H Farkas N Winter J Dobrowolny H S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric studyJ Psychiatr Res2008a 42868876

    Not in our library10.1016/j.jpsychires.2007.10.001

  220. 220.

    Steiner J Bielau H Brisch R Danos P Ullrich O Mawrin C Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicideJ Psychiatr Res2008b 42151157

    Not in our library10.1016/j.jpsychires.2006.10.013

  221. 221.

    Stevens CD Altshuler LL Bogerts B Falkai P Quantitative study of gliosis in schizophrenia and Huntington's choreaBiol Psychiatry1988a 24697700

    Not in our library10.1016/0006-3223(88)90144-8

  222. 222.

    Stevens J Casanova M Bigelow L Gliosis in schizophreniaBiol Psychiatry1988b 24727731

    Not in our library10.1016/0006-3223(88)90154-0

  223. 223.

    Togo T Akiyama H Kondo H Ikeda K Kato M Iseki E Expression of CD40 in the brain of Alzheimer's disease and other neurological diseasesBrain Res2000 885117121

    Not in our library10.1016/s0006-8993(00)02984-x

  224. 224.

    Wierzba-Bobrowicz T Lewandowska E Kosno-Kruszewska E Lechowicz W Pasennik E Schmidt-Sidor B Degeneration of microglial cells in frontal and temporal lobes of chronic schizophrenicsFolia Neuropathol2004 42157165

    Not in our library

  225. 225.

    Wierzba-Bobrowicz T Lewandowska E Lechowicz W Stepień T Pasennik E Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenicsFolia Neuropathol2005 438189

    Not in our library

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.